z-logo
open-access-imgOpen Access
Tedizolid as Step-Down Therapy following Daptomycin versus Continuation of Daptomycin against Enterococci and Methicillin- and Vancomycin-Resistant Staphylococcus aureus in a Rat Endocarditis Model
Author(s) -
Kavindra V. Singh,
César A. Arias,
Barbara E. Murray
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02303-19
Subject(s) - daptomycin , enterococcus faecium , enterococcus faecalis , medicine , vancomycin , staphylococcus aureus , gentamicin , endocarditis , enterococcus , microbiology and biotechnology , ceftriaxone , ampicillin , infective endocarditis , antibiotics , methicillin resistant staphylococcus aureus , bacteria , biology , genetics
Tedizolid (TZD) and daptomycin (DAP) were assessed in a rat endocarditis model against Enterococcus faecalis , Enterococcus faecium (resistant to vancomycin and ampicillin), and Staphylococcus aureus As a monotherapy, TZD for 5 days was not effective in a comparison with no-treatment controls, while DAP for 5 days was significantly effective against these bacteria. Step-down therapy (DAP for 3 days followed by TZD for 2 days) was as effective as DAP for 5 days and was comparable to 3 days of DAP plus ceftriaxone against all bacteria and to 3 days of DAP plus gentamicin against E. faecalis OG1RF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here